Advertisement

Expert Point of View: Mark Crowther, MD, MSc, FRCPC


Advertisement
Get Permission

Mark Crowther, MD, MSc, FRCPC

Mark Crowther, MD, MSc, FRCPC

Session moderator Mark Crowther, MD, MSc, FRCPC, Professor of Clinical Epidemiology and Biostatistics and Leo Pharma Chair in Thromboembolism Research at McMaster University, in Ontario, Canada, said that the results of the PAUSE study provide the most definitive evidence to date regarding how individuals taking direct oral anticoagulants (DOACs) can manage their medication around the time of an elective surgery or procedure.

“These data suggest that patients can safely stop taking their DOACs in a very organized fashion based on bleeding risk,” said Dr. Crowther. “This study will almost instantaneously establish a treatment practice and standard for the vast number of patients in North America and around the world who take these drugs.” 

DISCLOSURE: Dr. Crowther has reported financial relationships with Alexion, Alnylam, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, Octapharma, and Pfizer.


Related Articles

PAUSE Study Establishes Simple Approach to Perioperative Management of Direct Oral Anticoagulants

The largest study to date addressing the common problem of perioperative direct oral anticoagulant (DOAC) management has shown that patients with atrial fibrillation can safely stop taking their anticoagulant for 1 day before and after procedures with a low risk of bleeding and for 2 days before...

Advertisement

Advertisement



;
Advertisement